International GAAP® 2019: Generally Accepted Accounting Practice under International Financial Reporting Standards

Home > Other > International GAAP® 2019: Generally Accepted Accounting Practice under International Financial Reporting Standards > Page 520
International GAAP® 2019: Generally Accepted Accounting Practice under International Financial Reporting Standards Page 520

by International GAAP 2019 (pdf)


  value of £5, conditional upon continuous service and performance targets over a 3-year period from grant

  date. The number of shares awarded varies according to the extent to which targets (all non-market vesting

  conditions) have been met, and could result in each employee still in service at the end of year 3 receiving a

  minimum of 600, and a maximum of 1,000 shares.

  Half way through year 2 (i.e. 18 months after grant date), A is acquired by B, following which A cancels all

  of its share awards. At the time of the cancellation, 130 of the original 150 employees were still in

  employment. At that time, it was A’s best estimate that, had the award run to its full term, 120 employees

  would have received 900 shares each. Accordingly the cumulative expense recognised by A for the award as

  at the date of takeover would, under the normal estimation processes of IFRS 2 discussed at 6.1 to 6.4 above,

  be £270,000 (900 shares × 120 employees × £5 × 18/36).

  How should A account for the cancellation of this award?

  Share-based

  payment

  2605

  The opening phrase of paragraph 28(a) – ‘the entity shall account for the cancellation ... as an acceleration

  of vesting’ – suggests that A should recognise a cost for all 130 employees in service at the date of

  cancellation. However, the following phrase – ‘[the entity] shall therefore recognise immediately the

  amount that would otherwise have been recognised for services received over the remainder of the vesting

  period’ – suggests that the charge should be based on only 120 employees, the best estimate, as at the date

  of cancellation of the number of employees in whom shares will finally vest. In our view, either reading

  of paragraph 28(a) is possible.

  There is then the issue of the number of shares per employee that should be taken into account in the

  cancellation charge. Should this be 1,000 shares per employee (the maximum number that could vest) or

  900 shares per employee (the number expected by the entity at the date of cancellation actually to vest)?

  In our view, it is unclear from the standard whether the intention was that the cancellation charge should be

  based on the number of shares considered likely, as at the date of cancellation, to vest for each employee

  (900 shares in this example) or whether it should be based on the maximum number of shares (1,000 shares

  in this example). Given the lack of clarity, in our view an entity may make an accounting policy choice.

  In extreme cases, the entity’s best estimate, as at the date of cancellation, might be that

  no awards are likely to vest. In this situation, no cancellation expense would be

  recognised. However, there would need to be evidence that this was not just a rather

  convenient assessment made as at the date of cancellation. Typically, the previous

  accounting periods would also have reflected a cumulative IFRS 2 expense of zero on

  the assumption that the awards would never vest.

  An effect of these requirements is that IFRS 2 creates an accounting arbitrage between

  an award that is ‘out of the money’ but not cancelled (the cost of which continues to be

  spread over the remaining period to vesting) and one which is formally cancelled (the

  cost of which is recognised immediately). Entities might well prefer to opt for

  cancellation so as to create a ‘one-off’ charge to earnings rather than continue to show,

  particularly during difficult trading periods, significant periodic costs for options that no

  longer have any real value. However, such early cancellation of an award precludes any

  chance of the cost of the award being reversed through forfeiture during, or at the end

  of, the vesting period if the original vesting conditions are not met.

  7.4.4 Replacement

  awards

  The required accounting treatment of replacement awards, whilst generally clear,

  nevertheless raises some issues of interpretation. Most of this sub-section addresses the

  replacement of unvested awards but the treatment of vested awards is addressed

  at 7.4.4.C below.

  As set out at 7.4 above, a new award that meets the criteria in paragraph 28(c) of IFRS 2

  to be treated as a replacement of a cancelled or settled award is accounted for as a

  modification of the original award and any incremental value arising from the granting

  of the replacement award is recognised over the vesting period of that replacement

  award. Where the criteria are not met, the new equity instruments are accounted for as

  a new grant (in addition to accounting for the cancellation or settlement of the original

  arrangement). The requirements are discussed in more detail below.

  7.4.4.A

  Designation of award as replacement award

  Whether or not an award is a ‘replacement’ award (and therefore recognised at only its

  incremental, rather than its full, fair value) is determined by whether or not the entity

  designates it as such on the date that it is granted. In other words, the accounting

  2606 Chapter 30

  treatment effectively hinges on declared management intent, notwithstanding the

  IASB’s systematic exclusion of management intent from many other areas of financial

  reporting. The Basis for Conclusions does not really explain the reason for this

  approach, which is also hard to reconcile with the fact that the value of an award is

  unaffected by whether, or when, the entity declares it to be a ‘replacement’ award for

  the purposes of IFRS 2. Presumably, the underlying reason is to prevent a retrospective,

  and possibly opportunistic, assertion that an award that has been in issue for some time

  is a replacement for an earlier award.

  Entities need to ensure that designation occurs on grant date as defined by IFRS 2

  (see 5.3 above). For example, if an entity cancels an award on 15 March and notifies an

  employee in writing on the same day of its intention to ask the remuneration committee

  to grant replacement options at its meeting two months later, on 15 May, such

  notification (although formal and in writing) may not strictly meet IFRS 2’s requirement

  for designation on grant date (i.e. 15 May). However, in our view, what is important is

  that the entity establishes a clear link between the cancellation of the old award and the

  granting of a replacement award even if there is later formal approval of the replacement

  award following the communication of its terms to the counterparty at the same time as

  the cancellation of the old award.

  As drafted, IFRS 2 gives entities an apparently free choice to designate any newly

  granted awards as replacement awards. In our view, however, such designation cannot

  credibly be made unless there is evidence of some connection between the cancelled

  and replacement awards. This might be that the cancelled and replacement awards

  involve the same counterparties, or that the cancellation and replacement are part of

  the same arrangement.

  7.4.4.B

  Incremental fair value of replacement award

  Where an award is designated as a replacement award, any incremental fair value must

  be recognised over the vesting period of the replacement award. The incremental fair

  value is the difference between the fair value of the replacement award and the ‘net fair

  value’ of the cancelled or settled award, both measured at the date on which the

  re
placement award is granted. The net fair value of the cancelled or settled award is the

  fair value of the award, immediately before cancellation, less any compensation

  payment that is accounted for as a deduction from equity. [IFRS 2.28(c)]. Thus the ‘net fair

  value’ of the original award can never be less than zero (since any compensation

  payment in excess of the fair value of the cancelled award would be accounted for in

  profit or loss, not in equity – see Example 30.27 at 7.4.3 above).

  There is some confusion within IFRS 2 as to whether a different accounting treatment

  is intended to result from, on the one hand, modifying an award and, on the other hand,

  cancelling it and replacing it with a new award on the same terms as the modified award.

  This is explored in the discussion of Example 30.29 below, which is based on the same

  fact pattern as Example 30.19 at 7.3.1.A above.

  Share-based

  payment

  2607

  Example 30.29: Replacement awards – is there an accounting arbitrage between

  accounting for a modification and accounting for cancellation

  and a new grant?

  At the beginning of year 1, an entity grants 100 share options to each of its 500 employees. Each grant is

  conditional upon the employee remaining in service over the next three years. The entity estimates that the

  fair value of each option is €15.

  By the end of year 1, the entity’s share price has dropped. The entity cancels the existing options and issues

  options which it identifies as replacement options, which also vest at the end of year 3. The entity estimates

  that, at the date of cancellation, the fair value of each of the original share options granted is €5 and that the

  fair value of each replacement share option is €8.

  40 employees leave during year 1. The entity estimates that a further 70 employees will leave during years 2

  and 3, so that there will be 390 employees at the end of year 3 (500 – 40 – 70).

  During year 2, a further 35 employees leave, and the entity estimates that a further 30 employees will leave

  during year 3, so that there will be 395 employees at the end of year 3 (500 – 40 – 35 – 30).

  During year 3, 28 employees leave, and hence a total of 103 employees ceased employment during the

  original three year vesting period, so that, for the remaining 397 employees, the replacement share options

  vest at the end of year 3.

  The intention of the IASB appears to have been that the arrangement should be accounted for in exactly the

  same way as the modification in Example 30.19 above, since the Basis for Conclusions to IFRS 2 notes:

  ‘...the Board saw no difference between a repricing of share options and a cancellation of share options

  followed by the granting of replacement share options at a lower exercise price, and therefore concluded

  that the accounting treatment should be the same.’ [IFRS 2.BC233].

  However, it is not clear that this intention is actually reflected in the drafting of IFRS 2, paragraph 28 of

  which reads as follows:

  ‘If a grant of equity instruments is cancelled or settled during the vesting period (other than a grant

  cancelled by forfeiture when the vesting conditions are not satisfied):

  (a) the entity shall account for the cancellation or settlement as an acceleration of vesting, and shall

  therefore recognise immediately the amount that otherwise would have been recognised for services

  received over the remainder of the vesting period.

  (b) any payment made to the employee on the cancellation or settlement of the grant shall be accounted

  for as the repurchase of an equity interest, i.e. as a deduction from equity, except to the extent that the

  payment exceeds the fair value of the equity instruments granted, measured at the repurchase date. Any

  such excess shall be recognised as an expense. [...]

  (c) if new equity instruments are granted to the employee and, on the date when those new equity

  instruments are granted, the entity identifies the new equity instruments granted as replacement equity

  instruments for the cancelled equity instruments, the entity shall account for the granting of replacement

  equity instruments in the same way as a modification of the original grant of equity instruments, in

  accordance with paragraph 27 and the guidance in Appendix B. [...]’. [IFRS 2.28].

  As a matter of natural construction, paragraph (a) requires the cancellation of the existing award to be treated

  as an acceleration of vesting – explicitly and without qualification. In particular there is no rider to the effect

  that the requirement of paragraph (a) is to be read as ‘subject to paragraph (c) below’.

  Paragraph (c) requires any ‘new equity instruments’ granted to be accounted for in the same way as a

  modification of the original grant of equity instruments. It does not require this treatment for the cancellation

  of the original instruments, because this has already been addressed in paragraph (a).

  Moreover, in order to construe paragraphs (a) and (c) in a manner consistent with the Basis for Conclusions

  to the standard, it would be necessary to read paragraph (c) as effectively superseding paragraph (a). However,

  for this to be a valid reading, it would also be necessary to read paragraph (b) as also superseding paragraph

  (a), and this would produce a manifestly incorrect result, namely that, if an award is cancelled and settled,

  there is no need ever to expense any part of the cancelled award not yet expensed at the date of cancellation.

  2608 Chapter 30

  The application of, firstly, the main text of IFRS 2 and, secondly, the Basis for Conclusions to IFRS 2 to the

  entity in Example 30.29 is set out below.

  The main text in IFRS 2 appears to require the entity to recognise:

  • The entire cost of the original options at the end of year 1 (since cancellation has the effect that they are

  treated as vesting at that date), based on the 390 employees expected at that date to be in employment at

  the end of the vesting period. This is not the only possible interpretation of the requirement of

  paragraph 28(a) – see below and the broader discussion in Example 30.28 at 7.4.3 above.

  • For the options replacing the 390 cancelled awards, the incremental fair value of the replacement options

  at repricing date (€3 per option, being the €8 fair value of each replacement option less the €5 fair value

  of each cancelled option) over a two year vesting period beginning at the date of cancellation (end of

  year 1), based on the (at first estimated and then actual) number of employees at the end of year 3 (i.e.

  the final number could be less than the estimate of 390).

  • For any additional replacement options (i.e. replacement options awarded in excess of the 390 × 100

  options that were expected to vest at cancellation date), the full incremental fair value at repricing date

  (being the €8 fair value of each replacement option) over a two year vesting period beginning at the

  repricing date (end of year 1). The expense is based on the (at first estimated and then actual) number of

  employees in excess of 390 at the end of year 3.

  This would be calculated as follows:

  Cumulative

  Expense for

  Year Calculation of cumulative expense

  expense (€)

  period (€)

  Original award

  Replacement award

  1 390 employees × 100

  options × €15

  –r />
  585,000

  585,000

  2 390 employees × 100

  390 employees × 100

  options × €15

  options × €3 × 1/2

  5 employees × 100

  options × €8 × 1/2

  645,500

  60,500

  3 390 employees × 100

  390 employees × 100

  options × €15

  options × €3

  7 employees × 100

  options × €8

  707,600

  62,100

  By contrast, the accounting treatment implied by the Basis for Conclusions is as follows (see Example 30.19 above):

  Cumulative

  Expense for

  Year Calculation of cumulative expense

  expense (€)

  period (€)

  Original award (a)

  Modified award (b)

  (a+b)

  1 390 employees × 100

  options × €15 × 1/3

  –

  195,000

  195,000

  2 395 employees × 100

  395 employees × 100

  options × €15 × 2/3

  options × €3 × 1/2

  454,250

  259,250

  3 397 employees × 100

  397 employees × 100

  options × €15

  options × €3

  714,600

  260,350

  It will be seen that both the periodic allocation of expense and the total expense differ

  under each interpretation. This is because, under the first interpretation, the cost of the

  original award is accelerated at the end of year 1 for all 390 employees expected at that

  date to be in employment at the end of the vesting period, whereas under the second

  interpretation a cost is recognised for the 397 employees whose awards finally vest. The

  difference between the two total charges of €7,000 (€714,600 – €707,600) represents

  397 – 390 = 7 employees @ €1,000 [100 options × €10[€15 + €3 – €8]] each = €7,000.

  Share-based

  payment

  2609

  We believe that either interpretation is valid, and an entity should adopt one or other

  consistently as a matter of accounting policy.

  In Example 30.29 above, we base the cancellation calculations on 390 employees (the

 

‹ Prev